HomeBUSINESS
BUSINESS

Maviret Retains Top Spot in Japan Drug Ranking in July-September: IQVIA
(Nov.8.2018)

AbbVie’s hepatitis C drug Maviret (glecaprevir + pibrentasvir) remained the top-selling drug in Japan in July-September, though its sales decelerated to 29,952 million yen from the previous quarter’s 42,386 million yen on an NHI price basis, IQVIA data show ...
(LOG IN FOR FULL STORY)